Skip to content



ASEP Peptide Technology involves small potent broad-spectrum anti-biofilm and anti-inflammatory peptides, that are highly active against all major clinically-relevant antibiotic resistant bacteria growing as biofilms as well as complex oral biofilms.

These proprietary peptides work synergistically with antibiotics and have been found effective in animal models of biofilm infections, including sinusitis and abscesses and have shown anti-Inflammatory activity as strong as nonsteroidal anti-inflammatory drug indomethacin.

The company is developing analogous peptides as immune modulators suppressing potentially harmful inflammation in relevant animal models while boosting protective innate immunity and peptides that combine these activities with anti-biofilm activity.

How it Works

ASEP Medical has developed a proprietary Peptide Technology that is to be applied during early medical Interventions to suppress Biofilm Regrowth and Reduce Inflammation.  This novel Peptide Technology shall directly address the ineffectiveness of current treatment options.

Clinical Trials

ASEP is pursuing clinical validation in the treatment of organisms associated with Sinusitis pathogens in a planned study in Vancouver, Canada with the current development efforts underway:

  • Screening of a large library of peptides for those with optimal activity against biofilms
  • In vitro Toxicity Study Requirements have been Identified
  • In vitro Anti-Inflammatory activities have been identified
  • Two (2) Sinusitis Mouse Models used to Demonstrate in vivo Activity of Peptides vs. Major Sinusitis Organisms have been developed,
  • Human Skin and Respiratory Air-Liquid Interface Organoids (Including a Damaged Tissue Model) to Demonstrate the Peptides’ Anti-Biofilm and Anti-Inflammatory ex vivo Activities have been created
  • New Formulations, Initial Pharmacokinetic Studies, and Assessed Toxicities have already been defined and/or developed

We've got big plans.

Don't miss another update.


  • A meta-analysis of >600 patients and further multinational clinical studies within our network of researchers involving >300 patients from Netherlands, Australia, Colombia and Canada (with another 200 currently being sequenced from Canada, USA and Australia) have been completed.
  • Studies have demonstrated that expression of the CR gene signature can predict severe sepsis in these patients.
  • Machine learning approaches have revealed multiple sub-signatures of 6-9 genes that are as effective as the original 31 gene signature.
  • These Biomarkers have been shown to have Greater Sensitivity and Specificity than SIRS Criteria to Identify or Rule Out Patients with Sepsis with Much Earlier. Recognition Time; (An Earlier and More Reliable Diagnosis results in More Precise Treatment and Improved Survival).
  • Studies are Underway to Prove that the Diagnosis of Groupings of Sepsis Patients (Endotypes of a Population) will enable Personalized Therapy.

Our Values

To continually innovate to address the global crisis of SEPSIS to improve survivability and quality of life of patients.


To combine the best scientific, development, and business teams necessary to achieve the unity goal of providing the best possible healthcare to those suffering with chronic infections.

Our Vision

To become the Global Market Leader in the Diagnosis and Treatment of SEPSIS.